JPMorgan analyst Anupam Rama lowered the firm’s price target on Vor Bio (VOR) to $40 from $43 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Vor Biopharma strengthens board following $150M private placement
- Vor Bio initiated with a Buy at TD Cowen
- Vor Bio prices 13.88M shares at $10.81 in private placement
- Vor Biopharma’s Telitacicept: A Promising Buy Amidst Valuation Disconnect and Strategic Focus on Unmet Needs
- Vor Biopharma Approves Stock Option Repricing Plan